Publicaties

Hieronder vindt u een overzicht van alle artikelen die zijn gepubliceerd op basis van gegevens uit de Hebon studie. Deze publicaties zijn tot stand gekomen dankzij de betrokkenheid van duizenden deelnemers. Voor elk artikel is een link opgenomen naar de bijbehorende pagina op PubMed, een openbare medische databank. Sommige artikelen zijn direct te lezen, maar voor anderen moet betaald worden om volledige toegang te krijgen via het tijdschrift zelf. Heeft u interesse in een specifieke publicatie? Neem dan gerust contact met ons op via hebon@nki.nl.

Stroot IAS, et al. High-grade serous carcinoma occurring after risk-reducing salpingo-oophorectomy in BRCA1/2 germline pathogenic variant carriers. J Natl Cancer Inst. 2025;117(4):719-27. [Full Text]
Beekman MJ, et al. No increased arterial stiffness after premenopausal risk-reducing salpingo-oophorectomy (RRSO). Maturitas. 2025;197:108265. [Full Text]
Andour L, et al. The TESTBREAST journey: Revisiting the importance of early detection by frequent screening of women at high risk of breast cancer. Int J Cancer. 2025. [Full Text]
van den Berg CB, et al. Does serous tubal intraepithelial carcinoma (STIC) metastasize? The clonal relationship between STIC and subsequent high-grade serous carcinoma in BRCA1/2 mutation carriers several years after risk-reducing salpingo-oophorectomy. Gynecol Oncol. 2024;187:113-9. [Full Text]
Terra L, et al. Urinary incontinence more than 15 years after premenopausal risk-reducing salpingo-oophorectomy: a multicentre cross-sectional study. BJOG. 2024;131(1):99-108. [Full Text]
Stroot IAS, et al. Long-term outcome of high-grade serous carcinoma established in risk-reducing salpingo-oophorectomy specimens in asymptomatic BRCA1/2 germline pathogenic variant carriers. Gynecol Oncol. 2024;187:198-203. [Full Text]
Schreurs MAC, et al. Cancer risks for other sites in addition to breast in CHEK2 c.1100delC families. Genet Med. 2024;26(9):101171. [Full Text]
Schreurs MAC, et al. The benefit of adding polygenic risk scores, lifestyle factors, and breast density to family history and genetic status for breast cancer risk and surveillance classification of unaffected women from germline CHEK2 c.1100delC families. Breast. 2024;73:103611. [Full Text]
Beekman MJ, et al. Coronary Artery Calcium Scores After Prophylactic Premenopausal Bilateral Salpingo-Oophorectomy. JACC CardioOncol. 2024;6(6):922-31. [Full Text]
van Barele M, et al. Contralateral breast cancer risk in patients with breast cancer and a germline-BRCA1/2 pathogenic variant undergoing radiation. J Natl Cancer Inst. 2023;115(11):1318-28. [Full Text]
Terra L, et al. Long-term effects of premenopausal risk-reducing salpingo-oophorectomy on cognition in women with high familial risk of ovarian cancer: A cross-sectional study. BJOG. 2023;130(8):968-77. [Full Text]
Terra L, et al. Sexual functioning more than 15 years after premenopausal risk-reducing salpingo-oophorectomy. Am J Obstet Gynecol. 2023;228(4):440 e1- e20. [Full Text]
Stroot IAS, et al. High-Grade Serous Carcinoma at Risk-Reducing Salpingo-Oophorectomy in Asymptomatic Carriers of BRCA1/2 Pathogenic Variants: Prevalence and Clinical Factors. J Clin Oncol. 2023;41(14):2523-35. [Full Text]
O'Mahony DG, et al. Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2. Br J Cancer. 2023;128(12):2283-94. [Full Text]
Muranen TA, et al. PREDICT validity for prognosis of breast cancer patients with pathogenic BRCA1/2 variants. NPJ Breast Cancer. 2023;9(1):37. [Full Text]
Lakeman IMM, et al. Clinical applicability of the Polygenic Risk Score for breast cancer risk prediction in familial cases. J Med Genet. 2023;60(4):327-36. [Full Text]
Kast K, et al. Associations of height, body mass index, and weight gain with breast cancer risk in carriers of a pathogenic variant in BRCA1 or BRCA2: the BRCA1 and BRCA2 Cohort Consortium. Breast Cancer Res. 2023;25(1):72. [Full Text]
Figlioli G, et al. Spectrum and Frequency of Germline FANCM Protein-Truncating Variants in 44,803 European Female Breast Cancer Cases. Cancers (Basel). 2023;15(13). [Full Text]
Figlioli G, et al. FANCM missense variants and breast cancer risk: a case-control association study of 75,156 European women. Eur J Hum Genet. 2023;31(5):578-87. [Full Text]
van Barele M, et al. Survival of BRCA1/BRCA2-associated pT1 breast cancer patients, a cohort study. Breast Cancer Res Treat. 2022;194(1):159-70. [Full Text]

Schrijver LH, et al. Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits. JNCI: Journal of the National Cancer Institute. 2022;114(4):540-52. [Full Text]
Koole SN, et al. Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial. Int J Cancer. 2022;151(8):1394-404. [Full Text]
Heemskerk-Gerritsen BAM, et al. Progression-free survival and overall survival after BRCA1/2-associated epithelial ovarian cancer: A matched cohort study. PLoS One. 2022;17(9):e0275015. [Full Text]
Hakkaart C, et al. Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers. Commun Biol. 2022;5(1):1061. [Full Text]
Hagenaars SC, et al. Longitudinal Serum Protein Analysis of Women with a High Risk of Developing Breast Cancer Reveals Large Interpatient Versus Small Intrapatient Variations: First Results from the TESTBREAST Study. Int J Mol Sci. 2022;23(20). [Full Text]
Giardiello D, et al. PredictCBC-2.0: a contralateral breast cancer risk prediction model developed and validated in ~ 200,000 patients. Breast Cancer Res. 2022;24(1):69. [Full T e xt]
Dorling L, et al. Breast cancer risks associated with missense variants in breast cancer susceptibility genes. Genome Med. 2022;14(1):51. [Full Text]
Dareng EO, et al. Polygenic risk modeling for prediction of epithelial ovarian cancer risk. Eur J Hum Genet. 2022;30(3):349-62. [Full Text]
Barnes DR, et al. Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores. J Natl Cancer Inst. 2022;114(1):109-22. [Full Text]
Akdeniz D, et al. Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study. Breast. 2022;61:98-107. [Full Text]
Terra L, et al. Long-Term Morbidity and Health After Early Menopause Due to Oophorectomy in Women at Increased Risk of Ovarian Cancer: Protocol for a Nationwide Cross-Sectional Study With Prospective Follow-Up (HARMOny Study). JMIR Res Protoc. 2021;10(1):e24414. [Full Text]
Schrijver LH, et al. Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study. Am J Obstet Gynecol. 2021;225(1):51 e1- e17. [Full Text]
Patuleia SIS, et al. Lessons Learned from Setting Up a Prospective, Longitudinal, Multicenter Study with Women at High Risk for Breast Cancer. Cancer Epidemiol Biomarkers Prev. 2021;30(3):441-9. [Full Text]
Lakeman IMM, et al. The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. Genet Med. 2021;23(9):1726-37. [Full Text]
de Jonge MM, et al. Endometrial Cancer Risk in Women With Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study. J Natl Cancer Inst. 2021;113(9):1203-11. [Full Text]
Coignard J, et al. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nat Commun. 2021;12(1):1078. [Full Text]
Breast Cancer Association C, et al. Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. N Engl J Med. 2021;384(5):428-39. [Full Text]
Zhang H, et al. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nat Genet. 2020;52(6):572-81. [Full Text]
Silvestri V, et al. Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). JAMA Oncol. 2020;6(8):1218-30. [Full Text]
Patel VL, et al. Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. Cancer Res. 2020;80(3):624-38. [Full Text]
Obdeijn IM, et al. The supplemental value of mammographic screening over breast MRI alone in BRCA2 mutation carriers. Breast Cancer Res Treat. 2020;181(3):581-8. [Full Text]
Muranen TA, et al. Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer. NPJ Breast Cancer. 2020;6:44. [Full Text]
Mavaddat N, et al. Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. 2020;22(1):8. [Full Text]
Li H, et al. Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Results from The BRCA1 and BRCA2 Cohort Consortium. Cancer Epidemiol Biomarkers Prev. 2020;29(2):368-78. [Full Text]
Hilbers FS, et al. Clustering of known low and moderate risk alleles rather than a novel recessive high-risk gene in non-BRCA1/2 sib trios affected with breast cancer. Int J Cancer. 2020;147(10):2708-16. [Full Text]
Feng H, et al. Transcriptome-wide association study of breast cancer risk by estrogen-receptor status. Genet Epidemiol. 2020;44(5):442-68. [Full Text]
Fachal L, et al. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nat Genet. 2020;52(1):56-73. [Full Text]
Barnes DR, et al. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genet Med. 2020;22(10):1653-66. [Full Text]
Qian F, et al. Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. J Natl Cancer Inst. 2019;111(4):350-64. [Full Text]
Qian F, et al. Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2019;121(2):180-92. [Full Text]
Lakeman IMM, et al. Addition of a 161-SNP polygenic risk score to family history-based risk prediction: impact on clinical management in non-BRCA1/2 breast cancer families. J Med Genet. 2019;56(9):581-9. [Full Text]
Heemskerk-Gerritsen BAM, et al. Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2019;177(3):723-33. [Full Text]
Friebel TM, et al. BRCA1 and BRCA2 pathogenic sequence variants in women of African origin or ancestry. Hum Mutat. 2019;40(10):1781-96. [Full Text]
Figlioli G, et al. The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. NPJ Breast Cancer. 2019;5:38. [Full Text]
Ferreira MA, et al. Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. Nat Commun. 2019;10(1):1741. [Full Text]
de Jonge MM, et al. Germline BRCA-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity. Clin Cancer Res. 2019;25(24):7517-26. [Full Text]
Terry MB, et al. The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With BRCA1 or BRCA2 Mutations. JNCI Cancer Spectr. 2018;2(4):pky078. [Full Text]
Teixeira N, et al. The association between cancer family history and ovarian cancer risk in BRCA1/2 mutation carriers: can it be explained by the mutation position? Eur J Hum Genet. 2018;26(6):848-57. [Full Text]
Schrijver LH, et al. Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study. JNCI Cancer Spectr. 2018;2(2):pky023. [Full Text]
Rebbeck TR, et al. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat. 2018;39(5):593-620. [Full Text]
Moghadasi S, et al. The BRCA1 c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium. J Med Genet. 2018;55(1):15-20. [Full Text]
Derks-Smeets IAP, et al. Ovarian stimulation for IVF and risk of primary breast cancer in BRCA1/2 mutation carriers. Br J Cancer. 2018;119(3):357-63. [Full Text]
Colombo M, et al. The BRCA2 c.68-7T > A variant is not pathogenic: A model for clinical calibration of spliceogenicity. Hum Mutat. 2018;39(5):729-41. [Full Text]
Walker LC, et al. Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers. Eur J Hum Genet. 2017;25(4):432-8. [Full Text]
Phelan CM, et al. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nat Genet. 2017;49(5):680-91. [Full Text]
Milne RL, et al. Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nat Genet. 2017;49(12):1767-78. [Full Text]
Lecarpentier J, et al. Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. J Clin Oncol. 2017;35(20):2240-50. [Full Text]
Kuchenbaecker KB, et al. Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. J Natl Cancer Inst. 2017;109(7). [Full Text]
Kuchenbaecker KB, et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA. 2017;317(23):2402-16. [Full Text]
Hamdi Y, et al. Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Res Treat. 2017;161(1):117-34. [Full Text]
Zeng C, et al. Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Res. 2016;18(1):64. [Full Text]
Vos JR, et al. Bias Explains Most of the Parent-of-Origin Effect on Breast Cancer Risk in BRCA1/2 Mutation Carriers. Cancer Epidemiol Biomarkers Prev. 2016;25(8):1251-8. [Full Text]
Vigorito E, et al. Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS One. 2016;11(7):e0158801. [Full Text]
van Tilborg TC, et al. Do BRCA1/2 mutation carriers have an earlier onset of natural menopause? Menopause. 2016;23(8):903-10. [Full Text]
Silvestri V, et al. Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res. 2016;18(1):15. [Full Text]
Rebbeck TR, et al. Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. Breast Cancer Res. 2016;18(1):112. [Full Text]
Ovarian Cancer Association Consortium BCAC, et al. No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecol Oncol. 2016;141(2):386-401. [Full Text]
Meeks HD, et al. BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. J Natl Cancer Inst. 2016;108(2). [Full Text]
Lawrenson K, et al. Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. Nat Commun. 2016;7:12675. [Full Text]
Fehringer G, et al. Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations. Cancer Res. 2016;76(17):5103-14. [Full Text]
Dunning AM, et al. Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nat Genet. 2016;48(4):374-86. [Full Text]
Wevers MR, et al. Timing of risk reducing mastectomy in breast cancer patients carrying a BRCA1/2 mutation: retrospective data from the Dutch HEBON study. Fam Cancer. 2015;14(3):355-63. [Full Text]
Rebbeck TR, et al. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA. 2015;313(13):1347-61. [Full Text]
Peterlongo P, et al. Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev. 2015;24(1):308-16. [Full Text]
Kuchenbaecker KB, et al. Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nat Genet. 2015;47(2):164-71. [Full Text]
Heemskerk-Gerritsen BA, et al. Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction. J Natl Cancer Inst. 2015;107(5). [Full Text]
Heemskerk-Gerritsen BA, et al. Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis. Int J Cancer. 2015;136(3):668-77. [Full Text]
Blein S, et al. An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Res. 2015;17(1):61. [Full Text]
Blanco I, et al. Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers. PLoS One. 2015;10(4):e0120020. [Full Text]
Vos JR, et al. Variation in mutation spectrum partly explains regional differences in the breast cancer risk of female BRCA mutation carriers in the Netherlands. Cancer Epidemiol Biomarkers Prev. 2014;23(11):2482-91. [Full Text]
Spurdle AB, et al. Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. Breast Cancer Res. 2014;16(6):3419. [Full Text]
Saadatmand S, et al. Relevance and efficacy of breast cancer screening in BRCA1 and BRCA2 mutation carriers above 60 years: a national cohort study. Int J Cancer. 2014;135(12):2940-9. [Full Text]
Osorio A, et al. DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. PLoS Genet. 2014;10(4):e1004256. [Full Text]
Kuchenbaecker KB, et al. Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. 2014;16(6):3416. [Full Text]
Brohet RM, et al. Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations. J Med Genet. 2014;51(2):98-107. [Full Text]
Phillips KA, et al. Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2013;31(25):3091-9. [Full Text]
Michailidou K, et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet. 2013;45(4):353-61, 61e1-2. [Full Text]
Gaudet MM, et al. Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. PLoS Genet. 2013;9(3):e1003173. [Full Text]
Couch FJ, et al. Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet. 2013;9(3):e1003212. [Full Text]
Bojesen SE, et al. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet. 2013;45(4):371-84, 84e1-2. [Full Text]
Stevens KN, et al. Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriers. Breast Cancer Res Treat. 2012;136(1):295-302. [Full Text]
Ramus SJ, et al. Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Hum Mutat. 2012;33(4):690-702. [Full Text]
Pijpe A, et al. Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK). BMJ. 2012;345:e5660. [Full Text]
Mavaddat N, et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev. 2012;21(1):134-47. [Full Text]
Laitman Y, et al. The KL-VS sequence variant of Klotho and cancer risk in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2012;132(3):1119-26. [Full Text]
Kirchhoff T, et al. Breast cancer risk and 6q22.33: combined results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2. PLoS One. 2012;7(6):e35706. [Full Text]
Jakubowska A, et al. Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study. Br J Cancer. 2012;106(12):2016-24. [Full Text]
Ghoussaini M, et al. Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet. 2012;44(3):312-8. [Full Text]
Ding YC, et al. A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev. 2012;21(8):1362-70. [Full Text]
Couch FJ, et al. Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev. 2012;21(4):645-57. [Full Text]
Antoniou AC, et al. Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. Breast Cancer Res. 2012;14(1):R33. [Full Text]
Spurdle AB, et al. Common genetic variation at BARD1 is not associated with breast cancer risk in BRCA1 or BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev. 2011;20(5):1032-8. [Full Text]
Ramus SJ, et al. Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 2011;103(2):105-16. [Full Text]
Pijpe A, et al. Validation study suggested no differential misclassification of self-reported mammography history in BRCA1/2 mutation carriers. J Clin Epidemiol. 2011;64(12):1434-43. [Full Text]
Pharoah PD, et al. The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin Cancer Res. 2011;17(11):3742-50. [Full Text]
Osorio A, et al. Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2. Br J Cancer. 2011;104(8):1356-61. [Full Text]
Mulligan AM, et al. Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res. 2011;13(6):R110. [Full Text]
Maxwell CA, et al. Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer. PLoS Biol. 2011;9(11):e1001199. [Full Text]
Martrat G, et al. Exploring the link between MORF4L1 and risk of breast cancer. Breast Cancer Res. 2011;13(2):R40. [Full Text]
Manders P, et al. Body weight and risk of breast cancer in BRCA1/2 mutation carriers. Breast Cancer Res Treat. 2011;126(1):193-202. [Full Text]
Im KM, et al. Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. Hum Genet. 2011;130(5):685-99. [Full Text]
Cox DG, et al. Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers. Hum Mol Genet. 2011;20(23):4732-47. [Full Text]
Antoniou AC, et al. Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet. 2011;20(16):3304-21. [Full Text]
Wang X, et al. Common variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers. Hum Mol Genet. 2010;19(14):2886-97. [Full Text]
Walker LC, et al. Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2 mutation carriers. Breast Cancer Res. 2010;12(6):R102. [Full Text]
Pijpe A, et al. Reliability of self-reported diagnostic radiation history in BRCA1/2 mutation carriers. Eur J Epidemiol. 2010;25(2):103-13. [Full Text]
Pijpe A, et al. Physical activity and the risk of breast cancer in BRCA1/2 mutation carriers. Breast Cancer Res Treat. 2010;120(1):235-44. [Full Text]
Jakubowska A, et al. The Leu33Pro polymorphism in the ITGB3 gene does not modify BRCA1/2-associated breast or ovarian cancer risks: results from a multicenter study among 15,542 BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2010;121(3):639-49. [Full Text]
Gaudet MM, et al. Common genetic variants and modification of penetrance of BRCA2-associated breast cancer. PLoS Genet. 2010;6(10):e1001183. [Full Text]

Engel C, et al. Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev. 2010;19(11):2859-68. [Full Text]
Antoniou AC, et al. A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet. 2010;42(10):885-92. [Full Text]
Antoniou AC, et al. Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res. 2010;70(23):9742-54. [Full Text]
Sinilnikova OM, et al. The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2009;101(8):1456-60. [Full Text]
Osorio A, et al. Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA). Br J Cancer. 2009;101(12):2048-54. [Full Text]
Johnatty SE, et al. No evidence that GATA3 rs570613 SNP modifies breast cancer risk. Breast Cancer Res Treat. 2009;117(2):371-9. [Full Text]
Antoniou AC, et al. Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet. 2009;18(22):4442-56. [Full Text]
Antoniou AC, et al. Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiol Biomarkers Prev. 2009;18(2):601-10. [Full Text]
Antoniou AC, et al. Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet. 2008;82(4):937-48. [Full Text]
Chenevix-Trench G, et al. An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA). Breast Cancer Res. 2007;9(2):104. [Full Text]
Chang-Claude J, et al. Age at menarche and menopause and breast cancer risk in the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiol Biomarkers Prev. 2007;16(4):740-6. [Full Text]
Brohet RM, et al. Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group. J Clin Oncol. 2007;25(25):3831-6. [Full Text]
Andrieu N, et al. Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS). J Natl Cancer Inst. 2006;98(8):535-44. [Full Text]
Andrieu N, et al. Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study: a report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators' Group. J Clin Oncol. 2006;24(21):3361-6. [Full Text]
van Asperen CJ, et al. Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet. 2005;42(9):711-9. [Full Text]
Antoniou AC, et al. A weighted cohort approach for analysing factors modifying disease risks in carriers of high-risk susceptibility genes. Genet Epidemiol. 2005;29(1):1-11. [Full Text]
Goldgar D, et al. The International BRCA1/2Carrier Cohort Study: Purpose, Rationale, and Study Design. Breast Cancer Research. 2000;2(6):E010. [Full Text]

Laatst aangepast juni 2025